76

Apolipoprotein E; Potential Novel Therapy for Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) is a genetic bone disorder. Affected children typically have fragile bones and short stature. Currently, bisphosphonates are the standard treatment for bone fragility, however, there is no such treatment for growth deficiency. Our previous clinical trials of mesenchymal stem/stromal cell (MSC) therapy for patients with OI showed growth acceleration. In an effort to identify the mechanism underlying bone growth after MSC infusion, we identified a candidate molecule from the serum of MSC infused mice, which has potential to improve both bone growth and bone fragility. This molecule can be used as a novel therapy for OI.